Tests two chemotherapy plans for early stage Hodgkin lymphoma
Compares standard ABVD chemotherapy with A2VD, adding brentuximab vedotin, in early Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Key facts
- Where
- Halifax, Hamilton, Ottawa, Saint John, Toronto, Vancouver, and Winnipeg, CanadaSee the 7 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 69 years old?
Source: NCT04685616, who can take part
Where in Canada
- QEII Health Sciences CentreHalifax, CanadaTaking people
- Juravinski Cancer CentreHamilton, CanadaTaking people
- Ottowa Hospital Research InstituteOttawa, CanadaTaking people
- Saint John Regional HospitalSaint John, CanadaTaking people
- University Health Network - Princess Margaret Cancer CentreToronto, CanadaTaking people
- Vancouver Cancer CentreVancouver, CanadaTaking people
- CancerCare ManitobaWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University College, London
- Trial code
- NCT04685616EU 2022-500031-37-00
- Record updated
- 8 July 2026
- Original description
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.Read full original descriptionShow less
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.
Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy.
An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.
Patients will be followed up for a minimum of 5 years after treatment.
Inclusion: Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU); Histologically confirmed classical Hodgkin lymphoma; Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable; ECOG performance status 0-2; No previous treatment for Hodgkin lymphoma; Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%); Creatinine clearance (measured or calculated >40ml/min; Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome; ALT or AST < 2 x upper limit of normal; Adequate bone marrow function with neutrophils ≥1.0x10\^9/l and platelets ≥100x10\^9/l; Haemoglobin ≥8g/dL; Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable; Written informed consent.
Exclusion: Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days; Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose; Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry); Infradiaphragmatic disease; Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded; Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis; History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain; Symptomatic neurologic disease compromising normal activities of daily living or requiring medications; Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive); Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD; Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration; Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous; Nodular lymphocyte predominant Hodgkin lymphoma; Age 70 years or over or age 15 years or under; Absence of FDG-avid lesions on baseline PET scan; Pre-existing grade ≥1 sensory or motor neuropathy from any cause; Pregnant or breastfeeding women.